亚洲国产精品成人无码A片软件 ,国产亚洲AV无码一区二区二三区,成午夜精品一区二区三区

Totrombopag choline

NMR下載 COA and HPLC MSDS下載
names：
2-hydroxy-N,N,N-trimethylethan-1-aminium (E)-5-(3'-((1-(3,4-dimethylphenyl)-3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-4-yl)diazenyl)-2'-hydroxy-[1,1'-biphenyl]-3-yl)tetrazol-1-ide
CAS號：
851606-62-7
MDL Number：
MF(分子式)： C30H35N9O3 MW(分子量)： 569.67
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

貨品編碼	規(guī)格	純度	價格 (￥)	現(xiàn)價(￥)	特價(￥)	庫存描述	數(shù)量	總計 (￥)

大包裝詢價提供各種包裝，敬請垂詢
收藏商品商品點(diǎn)評加入購物車立即購買

快速詢價

收起

你想詢價的產(chǎn)品

*產(chǎn)品名稱：

CAS號：

產(chǎn)品編號：

需求描述：

請準(zhǔn)確填寫您的聯(lián)系方式，以便為您提供最好的服務(wù)。

*公司名稱：

*電子郵箱：

聯(lián)系人：

*電話：

*驗(yàn)證碼：

詢價

中文別名	2-hydroxy-N,N,N-trimethylethan-1-aminium (E)-5-(3'-((1-(3,4-dimethylphenyl)-3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-4-yl)diazenyl)-2'-hydroxy-[1,1'-biphenyl]-3-yl)tetrazol-1-ide
英文別名	SB559448; SB 559448; SB-559448; LGD-4665; LGD4665; LGD 4665; GSK2285921; GSK-2285921; GSK 2285921; C116875; Totrombopag choline
CAS號	851606-62-7
Inchi	InChI=1S/C25H21N8O2.C5H14NO/c1-14-10-11-19(12-15(14)2)33-25(35)22(16(3)30-33)27-26-21-9-5-8-20(23(21)34)17-6-4-7-18(13-17)24-28-31-32-29-24;1-6(2,3)4-5-7/h4-13,22H,1-3H3,(H-,27,28,29,31,32,34);7H,4-5H2,1-3H3/q-1;+1
InchiKey	JKVHRBKMPPIUNC-UHFFFAOYSA-N
分子式 Formula	C30H35N9O3
分子量 Molecular Weight	569.67
溶解度Solubility
性狀	Solid powder
儲藏條件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

產(chǎn)品說明	Totrombopag choline(CAS:851606-62-7 ):僅限應(yīng)用于工業(yè)或者科學(xué)研究過程中非醫(yī)療目的，不應(yīng)用于人類或動物的臨床診斷以及治過程療，該產(chǎn)品非藥用，非食用。
Introduction	Totrombopag, also known LGD-4665, GSK2285921 and SB559448, is an oral thromobopoietin receptor agonist, is being developed as a new generation small molecule thrombopoietin (TPO) mimetic. It is a highly selective and potent agonist of the TPO receptor and therefore induces differentiation and proliferation of megakaryocytes. The pharmacologic characteristics indicate potential therapeutic use in thrombocytopenic patients with a variety of clinical etiologies.
Application1
Application2
Application3

警示圖
危險性	Warning
危險性警示
安全聲明
安全防護(hù)
備注

Therapy (2009), 3 151-157.3. Tomillero A; Moral M A Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology (2008), 30(7), 543-88.4. Bayes M; Rabasseda X Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology (2008), 30(1), 67-99.